For a study, researchers sought to assess the connection between body weight and the rate of supraventricular tachycardia (SVT) cessation following a 6-mg adenosine dose.

An electrophysiologic examination with an SVT diagnosis was performed on individuals who attended a single tertiary emergency department and were included in the retrospective observational investigation. Patients who were less than 18 years old, had SVT aberrancy, experienced recurrent SVT after radiofrequency catheter ablation, were taking non-dihydropyridine calcium channel blockers before the study, and showed indications of shock were also excluded.

They gathered information on 124 patients. The mean age was 49.7 years, and there were 69 women (55.6%). The average person weighed 66.8 kg and measured 164.8 cm tall. It contained 0.09 mg/kg of adenosine. The mean weight, height, and adenosine dose for the first sinus conversion (SC) success group (83 patients, 67%) were 61.0 ± 11.5 kg, 161.9 ± 8.1 cm, and 0.10 ± 0.02 mg/kg, respectively. These numbers were 78.4 ± 17.0 kg, 170.7 ± 8.9 cm, and 0.079 ± 0.02 mg/kg for the first SC failure group. They used to weight and height in a bivariate logistic regression to assess the variables that contributed to the first SC (odds ratio [OR]: 1.093; 95% CI: 1.045–1.144; P < 0.001) and height (OR: 1.071; 95% CI: 1.008–1.138; P = 0.027). Adenosine dosage and weight cut-off values were 0.90 mg/kg and 66.5 kg, respectively, with 71.1% sensitivity and 73.2% specificity (area under the curve: 0.814; 95% CI: 0.73-0.90; P< 0.001).

Among SVT patients, weight and height were important predictors of the first SC success rate. As a result, it was necessary to take into account alternative adenosine administration strategies, such as increasing the initial drug dose or altering the flushing method following adenosine injection.